Medication non-adherence among liver transplant recipients.
Medication non-adherence among liver transplant recipients.
复制标题
DOI：
10.1007/s11901-020-00545-7
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Serper M
中科院分区：
文献类型：
--
作者：
Jones LS;Serper M
我们提供了关于肝移植(LT)受者药物不依从性(NA)的患病率、危险因素和后果的最新证据的概述。LT的NA与社会人口学和药物相关因素、社会支持程度低和健康素养差有关。患者报告的依从性是使用有效的评估来衡量NA的最常见的方法之一；也可以使用免疫抑制(IS)药物水平和电子监测。简化IS方案，如从每天两次改为每天一次，已被证明是安全、有效的，并提高了依从性。相对较少的研究前瞻性地研究了在LT中降低NA的NA预测因素或干预措施。药物不依从性是一个多方面的问题，在LT受者中很常见，并与不良后果相关。肝移植受者的NA值得进一步研究，因为目前只有几种干预措施集中于减少肝移植中的NA。
We provide an overview of the recent evidence on the prevalence, risk factors, and consequences of medication non-adherence (NA) in liver transplant (LT) recipients. NA in LT is associated with socio-demographic and medication-related factors, low social support, and poor health literacy. Patient-reported adherence is one of the most common methods to measure NA using validated assessments; immunosuppression (IS) drug levels and electronic monitoring may also be used. Simplification of IS regimens such as the conversion from twice daily to once daily has been shown to be safe, effective, and improves adherence. Relatively few studies have prospectively investigated NA predictors or interventions to reduce NA in LT. Medication non-adherence is a multi-faceted issue that is common among LT recipients and associated with adverse outcomes. NA in LT recipients warrants further study as only a few interventions have been published focused on reducing NA in LT.